Pivotal NGN-401 trial speeds toward dosing for people with Rett
NGN-401, a gene therapy treatment people with Rett syndrome, has shown positive results from an ongoing Phase 1/2 trial.| Rett Syndrome News
NGN-401, a gene therapy treatment people with Rett syndrome, has shown positive results from an ongoing Phase 1/2 trial.| Rett Syndrome News
The first four Rett syndrome patients treated with the gene therapy candidate NGN-401 have seen meaningful gains in skills, data show.| Rett Syndrome News
The US regulatory agency acts to support the potential gene therapy's development, with ongoing Phase 1/2 trial showing safety in patients.| Rett Syndrome News
